title: Intra-articular controlled release of anti-inflammatory siRNA with biodegradable polymer microparticles ameliorates temporomandibular joint inflammation.
abstract: We investigated the in vivo therapeutic efficacy of an intra-articular controlled release system consisting of biodegradable poly(dl-lactic-co-glycolic acid) (PLGA) microparticles (MPs) encapsulating anti-inflammatory small interfering RNA (siRNA), together with branched poly(ethylenimine) (PEI) as a transfecting agent, in a rat model of painful temporomandibular joint (TMJ) inflammation. The in vivo effects of PLGA MP dose and siRNA-PEI polyplex delivery were examined via non-invasive meal pattern analysis and by quantifying the protein level of the siRNA target as well as of several downstream inflammatory cytokines. Controlled release of siRNA-PEI from PLGA MPs significantly reduced inflammation-induced changes in meal patterns compared to untreated rats with inflamed TMJs. These changes correlated to decreases in tissue-level protein expression of the siRNA target to 20-50% of the amount present in the corresponding control groups. Similar reductions were also observed in the expression of downstream inflammatory cytokines, e.g. interleukin-6, whose tissue levels in the siRNA-PEI PLGA MP groups were 50% of the values for the corresponding controls. This intra-articular sustained release system has significant implications for the treatment of severe TMJ pain, and also has the potential to be readily adapted and applied to mitigate painful, chronic inflammation in a variety of conditions.
authors: Department of Bioengineering, Rice University, Houston, TX 77251, USA.
authors: Paschalia M
authors: PM
authors: Mountziaris
authors: Stephanie N
authors: SN
authors: Tzouanas
authors: David C
authors: DC
authors: Sing
authors: Phillip R
authors: PR
authors: Kramer
authors: F Kurtis
authors: FK
authors: Kasper
authors: Antonios G
authors: AG
authors: Mikos
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D016207:Cytokines / Q000378:metabolism; D003692:Delayed-Action Preparations; D005247:Feeding Behavior; D015316:Genetic Therapy / Q000379:methods*; D007249:Inflammation / Q000235:genetics* / Q000473:pathology / Q000628:therapy*; D018836:Inflammation Mediators / Q000378:metabolism; D019344:Lactic Acid / Q000737:chemistry; D008297:Male; D008863:Microspheres; D010316:Particle Size; D011094:Polyethyleneimine / Q000737:chemistry; D011100:Polyglycolic Acid / Q000737:chemistry; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011108:Polymers / Q000737:chemistry*; D034741:RNA, Small Interfering / Q000008:administration & dosage* / Q000235:genetics; D051381:Rats; D017207:Rats, Sprague-Dawley; D017452:Receptors, IgG / Q000378:metabolism; D013704:Temporomandibular Joint / Q000378:metabolism* / Q000473:pathology*; D013997:Time Factors
chemical_list: D000893:Anti-Inflammatory Agents; D016207:Cytokines; D003692:Delayed-Action Preparations; D018836:Inflammation Mediators; D011108:Polymers; D034741:RNA, Small Interfering; D017452:Receptors, IgG; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid; D011094:Polyethyleneimine